25×25 KOL–Trial Matrices
For each tumor type, the top 25 physician voices are mapped against the top 25 clinical trials and ranked by the tweet engagement each KOL earned across the trial set. Read a row to see which trials a KOL owns the conversation on; read a column to see who is shaping the discussion around a given trial.
Lung Top 25 KOLs × Top 25 Trials
Peer-engagement heatmap of the 25 most influential lung-cancer voices against the 25 highest-signal lung trials, ranked by tweet engagement received across the trial set.
Breast Top 25 KOLs × Top 25 Trials
Peer-engagement heatmap of the 25 most influential breast-cancer voices against the 25 highest-signal breast trials, ranked by tweet engagement received across the trial set.
Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
Conference Influencer Networks
Who drove the social conversation at each 2026 congress. Each page maps the mention / retweet / quote network of the top KOLs, sizes nodes by impressions, and classifies accounts as KOLs, US physicians, institutions, or media.
ASCO 2026 Lung Influencer Networks
Who amplifies whom across the ASCO 2026 lung-cancer conversation — filter the network by any of 17 lung trials, from CROWN and WU-KONG28 to ROSETTA Lung-02.
ASCO 2026 Breast Influencer Networks
Who amplifies whom across the ASCO 2026 breast-cancer conversation — filter the network by any of 21 breast trials, from SERENA-6 and DESTINY-Breast to ASCENT-04, OPTIMA and INAVO120.
AACR 2026 Influencer Networks
The largest 2026 network on the platform — conversation drivers across the American Association for Cancer Research annual meeting.
EHA 2026 Influencer Networks
Conversation drivers across the European Hematology Association congress — leukemia, lymphoma, and myeloma voices.
ESMO GI 2026 Influencer Networks
Conversation drivers across the ESMO Gastrointestinal Cancers congress — colorectal, pancreatic, gastric, and HCC voices.
ESMO Breast 2026 Influencer Networks
Conversation drivers across the ESMO Breast Cancer congress — HR+, HER2+, and TNBC voices.
Conference Attendee Networks
The virtual-attendee view of each congress: a top-10 KOL strip, category and region breakdowns, and the ranked grid of the physicians, institutions, and media accounts most active during the meeting.
ASCO 2026 Lung Virtual Attendee Network
Category and region breakdown of the accounts driving ASCO 2026 lung-cancer discussion, filterable by lung trial with the top KOLs ranked by engagement.
ASCO 2026 Breast Virtual Attendee Network
Category and region breakdown of the accounts driving ASCO 2026 breast-cancer discussion, filterable by breast trial with the top KOLs ranked by engagement.
AACR 2026 Virtual Attendee Network
Category and region breakdown of every account active at AACR 2026, with the top KOLs ranked by impressions.
EHA 2026 Virtual Attendee Network
Category and region breakdown of every account active at EHA 2026, with the top hematology KOLs ranked by impressions.
ESMO GI 2026 Virtual Attendee Network
Category and region breakdown of every account active at ESMO GI 2026, with the top GI KOLs ranked by impressions.
ESMO Breast 2026 Virtual Attendee Network
Category and region breakdown of every account active at ESMO Breast 2026, with the top breast KOLs ranked by impressions.
ELCC 2026 Virtual Attendee Network
Category and region breakdown of the accounts active at the European Lung Cancer Congress 2026, with the top lung KOLs ranked by impressions.
Coming Soon
Two resources are in production from data compiled this ASCO 2026 cycle. These cards are placeholders — links go live as each page ships.
Top Tumor Influencers at ASCO 2026
A per-tumor-type ranking of the trials and KOLs that drove the ASCO 2026 conversation — built from real curated data across eight tumor types (lung, breast, GI, GU, myeloma, heme, melanoma, and other solid tumors). The underlying dataset is compiled; the page is in build.
KOL Profiles
Individual, publication-ready KOL profile pages — advisory-board networks, trial-discussion portfolios, sentiment trajectory, and featured moments — built to the locked v2 profile spec. Rolling out as ASCO 2026 data and profiles are finalized.